in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
PCI Synthesis: Increased regulatory scrutiny, wage inflations in India and China to impact industry in 2014
7:35 AM MST | December 10, 2013 | Deepti Ramesh
PCI Synthesis (Newburyport, MA), a manufacturer of new chemical entities, generic active pharmaceutical ingredients (APIs), complex pharmaceutical intermediates, and other specialty chemical products, has announced a list of trends that are likely to impact the generic drug and emerging biotech industries in 2014. The trends include increased regulatory scrutiny, drug shortages, wage inflations in India and China, a biotech bubble, and the challenge of finding qualified people. FDA—most recently with a bill signed into law in November 2013, the Drug Quality...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee